Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices 23731 

fresh frozen tissues. Vast availability of 

fresh frozen tissues and peripheral 

blood specimens that are easily obtained 

could lead to clinical tests amenable to 

therapeutic, prognostic and even early 

screening tests for renal cell carcinoma 

and other malignancies. 

Applications: Renal cell carcinoma 

diagnostics, therapeutics and 

prognostics. 

Market: 

• Cancer is the second leading cause 

of death in the U.S.A. There is an acute 

need for cancer biomarkers that can be 

detected from clinically relevant 

samples and used for early diagnosis, 

therapeutic follow-up and prognosis of 

malignant diseases. 

• The incidence of renal cell cancer 

has been rising steadily. Renal Cell 

Carcinoma is the most common type of 

kidney cancer, and the most common 

type in adults, responsible for 

approximately 80% of cases. 

Inventors: Josip Blonder et al. (NCI). 

Patent Status: PCT Application No. 

PCT/US2009/037855 filed 20 Mar 2009 

(HHS Reference No. E–317–2008/0– 

PCT–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Betty B. Tong, 

Ph.D.; 301–594–6565; 

tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute 

Laboratory of Proteomics and Analytical 

Technologies is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize diagnostic, therapeutic 

and prognostic cancer biomarkers from 

clinical specimens. Please contact John 

D. Hewes, Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Dated: May 13, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–11705 Filed 5–19–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary 

and Alternative Medicine 

Announcement of Workshop on the 

Non-Pharmacological Management of 

Back Pain 

ACTION: Notice. 

SUMMARY: The National Center for 

Complementary and Alternative 

Medicine (NCCAM) invites the research 

community to participate in an online 

Workshop on Non-Pharmacological 

Management of Back Pain. The purpose 

of this workshop is to identify and 

explore a range of important and timely 

clinical research questions related to 

non-pharmacological interventions to 

treat back pain. This information will 

help inform future research directions 

for NIH and the biomedical scientific 

field. This workshop will be split into 

three sessions that will feature 

presentations and discussions focusing 

on the current understanding and 

complexity of chronic back pain, 

promising questions associated with 

testable hypotheses, and the relevant 

outcome measures. 

The Workshop will take place on May 

27, 2009. Those interested in CAM 

research are particularly encouraged to 

view and participate. 

Background: The National Center for 

Complementary and Alternative 

Medicine (NCCAM) was established in 

1999 with the mission of exploring 

complementary and alternative healing 

practices in the context of rigorous 

science, training CAM researchers, and 

disseminating authoritative information 

to the public and professionals. NCCAM 

funds research grants that explore the 

science of CAM. For more information, 

see http://nccam.nih.gov/grants/ 

whatnccamfunds/. 

Participating: The Workshop will be 

broadcast on the Internet and archived 

on http://www.videocast.nih.gov/. 

Viewers may submit questions for the 

presenters and panelists by e-mailing 

nccambkpnwkshp@mail.nih.gov with 

questions or comments. For more 

information about what will be covered 

at the workshop, see http:// 

nccam.nih.gov/news/events/. 

FOR FURTHER INFORMATION CONTACT: To 

request more information, visit the 

NCCAM Web site at http:// 

nccam.nih.gov/news/events/, call 301– 

594–3391 (Edward Culhane) or e-mail at 

culhanee@mail.nih.gov. 

Dated: May 12, 2009. 

Richard Nahin, 

Senior Advisor for Scientific Coordination 

and Outreach, National Center for 

Complementary and Alternative Medicine, 

National Institutes of Health. 

[FR Doc. E9–11679 Filed 5–19–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Gastroenterology and Urology Devices 

Panel of the Medical Devices Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Gastroenterology 

and Urology Devices Panel of the 

Medical Devices Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on Wednesday, June 10, 2009, from 

8 a.m. to 5 p.m. 

Location: Holiday Inn, Ballroom, Two 

Montgomery Village Ave., Gaithersburg, 

MD. 

Contact Person: Megan Mickal, Center 

for Devices and Radiological Health 

(HFZ–470), Food and Drug 

Administration, 9200 Corporate Blvd., 

Rockville, MD 20850, 240–276–4151, or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

3014512523. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: The committee will discuss 

and make recommendations regarding 

general issues related to the use of 

ultrafiltration devices in the treatment 

of extracellular body fluid overload in 

patients experiencing heart failure. 

Specifically, the committee will address 

the use of these devices in patients 

experiencing heart failure in the 

following terms: Identifying the most 

appropriate heart failure patients for 

whom these treatments should be 

indicated, determining where these 

treatments fit within the spectrum of 

treatment options, and defining what 

level of clinical evidence is necessary to